Introduction
Mitogen-activated protein kinases (MAPK) are a group of serine/threonine-specific protein kinases which are activated by different extracellular stimuli. MAPK activation is achieved through kinase cascades, which include a MAPK kinase (MAPKK) and a MAPKK kinase (MAPKKK) (reviewed in 1,2). In yeast, four signal transduction modules with this basic character have been described (3) and a similar or even larger group of related pathways probably act to transmit signals in mammalian cells. At present, only three such pathways (involving as terminal elements the Erks, the SAPK and the p38 kinase) have been defined in detail in mammalian cells, although growing evidence for additional cascades exists (reviewed in 4).
The stress-activated protein kinase (SAPK) family includes at least 10 members (5) that are activated in response to cellular stress, inhibitors of protein synthesis, inflammatory cytokines (e.g. tumor necrosis factor-α and IL-1) and, in some cases, mitogens (reviewed in 6). Originally described as kinases which could bind to and phosphorylate the activation domain of transcription factor c-Jun (and hence also known as Received 20 February 1998, accepted 13 April 1998 Jun N-terminal kinases) (7, 8) , these elements are positioned within a conventional signaling cascade involving MKK1 (the MAPKKK), MKK4/Sek-1 (the MAPKK) and the SAPK themselves. A complete inventory of kinases that contribute to SAPK regulation remains elusive, in part because multiple SAPKK activities exist in cells (9, 10) and also because multiple proteins act as MAPKKK for MKK-4 (11). In general, the SAPK cascade is regulated by the small GTP-binding proteins Rac1 and Cdc24 (12) , although, in some cases, Ras also plays a role in its regulation (8) . In Jurkat T cells, the combinations of anti-CD3 and anti-CD28 antibodies, or of phorbol esters and ionomycin, synergize in activating this cascade (13) . Moreover, SAPK activation is inhibited by cyclosporine, suggesting that this cascade could serve to mediate converging signals from accessory receptors that are required for satisfactory co-stimulation of T cells in vivo (13) . In partial accord with this view, some recent studies suggest that activation of the SAPK is blocked in T cells rendered anergic through TCR stimulation in the absence of co-receptor input (14) (15) (16) . However SAPK activation does not uniquely result from CD28 stimulation. For example, triggering of Fas or CD40 in lymphocytes stimulates SAPK activity (17) (18) (19) . In light of the very different responses triggered by these multiple receptors the functional significance of SAPK activation remains enigmatic. While some reports correlate SAPK activation with apoptosis (20) (21) (22) (23) (24) , other experiments suggest that SAPK activation is not required in this process (17, (25) (26) (27) 
Methods

Generation of transgenic animals
A catalytically inactive MKK-4, generated by a single point mutation that results in a lysine-to-arginine substitution at position 129 (31) , was cloned into the BamHI site of the p1017 vector (32) . Purification and injection of the NotI fragment containing the transgene into (C57BL6/JϫDBA/2J)F 2 mouse zygote pronuclei proceeded as described (33) . Transgenic founders were detected by hybridization of genomic DNA with a human growth hormone probe, and stable lines of mice were generated by backcrossing founders with C57BL6/J mice (Jackson Laboratories, Bar Harbor, ME).
Flow cytometric analysis
Thymocytes were stained with saturating concentrations of antibody at 4°C for 30 min. Cells were examined for surface expression of the following molecules: CD4 (phycoerythrin-L3T4; Caltag, San Francisco, CA), CD8 (FITC-Ly-2, Caltag) and CD3ε (biotinylated 145-2C11; PharMingen, San Diego, CA). Biotinylated antibodies were visualized using trichromelabeled streptavidin (Caltag). Analyses were performed using a FACScan flow cytometer (Becton-Dickinson, San Jose, CA) under CellQuest software. Subsequent data analysis used ReproMac software (True Facts Software, Seattle, WA).
Western blotting
Thymocytes were lysed on ice for 15 min with lysis buffer (10 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 50 mM NaF, 0.4 mM Na 3 VO 4 , 10 mM iodoacetamide, 5 mM sodium pyrophosphate, 1 mM PMSF, and 1 mg/ ml aprotinin, leupeptin, pepstatin A and chymostatin) and the resulting lysate was centrifuged for 5 min at 15,000 g. The protein concentration in the supernatants was determined by the Bradford method. Lysates were fractionated by 10% SDS-PAGE gels under reducing conditions and then electrotransferred to nitrocellulose. The nitrocellulose filters were blocked for 45 min at 37°C and then incubated with primary antibody (anti-Mek-4; Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h. After three 5 min washes with PBS/01% Tween 20, the blots were incubated with horseradish peroxidase-conjugated sheep antimouse antiserum for 30 min, washed extensively and developed by enhanced chemiluminescence (Amersham, Arlington Heights, IL), according to the manufacturer's instructions.
Kinase assays After treatment of thymocytes with different agonists, cells were pelleted and solubilized in lysis buffer (20 mM HEPES, pH 7.4, 2 mM EGTA, 50 mM β-glycerophosphate, 1 mM DTT, 1 mM sodium orthovanadate, 1% Triton X-100, 10% glycerol, 2 mM leupeptin, 2 mM aprotinin and 100 mM PMSF) for 15 min on ice and centrifuged for 5 min. After immunoprecipitation with SAPK antibody (Santa Cruz Biotechnology) or p38 antibody (a generous gift from Dr R. Davis) and Protein ASepharose, the beads were washed 3 times in lysis buffer, twice in LiCl wash (500 mM LiCl, 100 mM Tris-HCl, pH 7.6, 0.1% Triton X-100 and 1 mM DTT) and twice in assay buffer (20 mM MOPS pH 7.2, 2 mM EGTA, 10 mM MgCl 2 , 1 mM EDTA and 0.1% Triton X-100). The kinase assay was performed by adding 2 µg of either GST-jun1-135 (SAPK) or GST-ATF (p38) fusion proteins (generous gifts from Dr R. Davis) in assay buffer, and Mg-ATP mix (50 mM MgCl 2 /0.5 mM [γ-32 P]ATP) and incubating for 20 min at 30°C. The reaction was stopped with 4ϫLaemlli buffer and the samples run in a 10% SDS-PAGE acrylamide gel and transferred to nitrocellulose.
In vitro deletion assay To analyze apoptosis of thymocytes in vitro, we coated 96-well round-bottom plates for 2 h at 37°C with antibodies [anti-CD3ε (145-2C11) and anti-Fas (Jo-2); PharMingen] in PBS at different concentrations. The plates were washed 4 times in PBS and 5ϫ10 5 cells were added to each well in a volume of 200 ml RPMI media with 10% FCS and incubated at 37°C. Cells were harvested 6 h later, stained with antibodies to CD4 (phycoerythrin conjugated; Caltag) and CD8 (FITC conjugated; Caltag), and analyzed for CD4 and CD8 expression, as described above. Viable cells retain high levels of CD4 and CD8 expression, while dead cells exhibit a decrease in staining intensity with these antibodies. In each experiment the basal survival value was that of cells incubated in uncoated plates.
In vivo deletion assays dMKK-4 transgenic animals and non-transgenic littermate controls (4-6-weeks old) were injected i.p. with 100 mg of purified anti-CD3 (145-2C11) in PBS or with PBS. After 24 h the animals were euthanized and their thymuses removed. The thymocytes were counted and stained with CD4 and CD8, as described above.
Results and discussion
To attenuate SAPK activation in thymocytes, we generated mice that overexpress a catalytically inactive MKK-4/Sek-1 (dMKK-4) containing a lysine-to-arginine substitution at position 129. Expression of this mutant blocks SAPK activation by different stimuli in a variety of cells (17, 31) . We expressed this mutant under the control of the lck proximal promoter, which directs expression of the transgene to thymocytes, as previously shown (32), generating three different lines of dMKK-4 transgenic animals expressing between 3-and 8-fold levels of immunoreactive MKK-4 protein as compared to littermate controls (Fig. 1A) .
Expression of the dMKK-4 transgene had no effect on the total number of thymocytes or in the distribution of different subpopulations of T cells in the thymus or spleen (Fig 1B) . Nevertheless SAPK activation in these cells was dramatically altered. In these experiments, freshly isolated thymocytes from control and transgenic animals were treated with different doses of phorbol myristate acetate (PMA) and ionomycin or with a plate-bound anti-Fas antibody for 30 min. After lysing Freshly isolated thymocytes from 4-to 6-week-old normal littermate control or transgenic animals were treated with anti-Fas antibodies bound to the plate (A) or with DMSO (carrier) (U) or ionomycin (100 ng/ml) and PMA at increasing doses (2, 10 and 50 ng/ml) (B) for 10 min. The stimulation was stopped with ice-cold PBS and the cells lysed. After clearing the lysates, SAPK and p38 were immunoprecipitated, and we performed in vitro kinase assays on the immunoprecipitates using GST-jun1-129 as the substrate for SAPK and GST-ATF2 as the substrate for p38, as described in Methods. The assays were run in a SDS-PAGE gel and transferred to nitrocellulose before being autoradiographed. Shown is one representative experiment out of three. (C) Activation of SAPK by anti-Fas antibodies in NLC versus dMKK-4 thymocytes. n ϭ 3. The intensity of the bands was quantified by densitometry the cells, SAPK and p38 were immunoprecipitated, and their activities assayed, using GST-jun and GST-ATF fusion proteins respectively as substrates. Figure 2(A) demonstrates that anti-Fas antibody treatment activates both p38-and SAPK-mediated SAPK phosphorylation of exogenous substrates in control thymocytes. When cells from dMKK-4 animals were assayed, however, no appreciable increase in SAPK activity was observed, despite strong activation of p38 ( Fig. 2A) . Quantitation of the assays revealed a 3-to 6-fold stimulation of SAPK activity in anti-Fas-treated control thymocytes, whereas SAPK activity could not be stimulated at all following incubation of dMKK-4 thymocytes with anti-Fas antibodies. We conclude that Fas-mediated activation of SAPK is mediated by MKK-4. To generalize this result we also examined thymocyte responses to traditional mitogenic stimuli, notably the combination of PMA and ionomycin treatment. To our surprise we observed no diminution in SAPK activation in dMKK-4 thymocytes treated in this way. Figure  2(B) shows that by increasing amounts of PMA in cells stimulated simultaneously with 100 ng/ml of ionomycin a 20-fold maximum increase in SAPK activation was observed in both wild-type and dMKK-4 thymocytes. Although Fasmediated activation of SAPK seemingly requires MKK-4, the combination of PMA and ionomycin can fully activate SAPK in the presence of an overwhelming excess of catalytically inactive MKK-4. The identification of the alternative SAPKK presumably responsible for the activation of the SAPK after stimulation with PMA and ionomycin or CD3 and CD28 would be very important, given the suggested role of SAPK in the control of proliferation (13) and anergy (14) (15) (16) . Although there is evidence of the existence of alternative SAPKK in other cell types (9,10) they have not yet been molecularly characterized, with the exception of MKK-7 (33, 34) .
Given the dramatic inhibition of Fas-induced SAPK activa- tion in the transgenic thymocytes and the controversy concerning SAPK's role in apoptosis in different systems (17, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , we analyzed the effect of dMKK-4 on thymocyte deletion in response to anti-CD3, PMA and anti-Fas. For these analyses, freshly isolated thymocytes were incubated with different doses of PMA or plate-bound anti-Fas and anti-CD3 antibodies, and 6 h later thymocytes were harvested and stained with antibodies against CD4 and CD8. The number of apoptotic cells was determined by flow cytometry criteria (see Methods). Remarkably, expression of dMKK-4 does not protect thymocytes from anti-CD3-, PMA-or anti-Fas-induced apoptosis ( Fig. 3A and data not shown), despite the profound inhibition of Fas-induced SAPK activation (Fig. 2B) . Although it remains plausible that a minimal increase in SAPK activity, undetectable using our assays, contributes to Fas-induced apoptosis of thymocytes, our results emphasize that SAPK activation cannot be limiting in apoptosis. This conclusion, derived from studies in otherwise normal cells, supports observations made previously in Jurkat lymphoblasts (17) and RAG reconstitution assays (26) , as well as in other systems (25) . To verify these in vitro studies, we also analyzed the effect of dMKK-4 on in vivo deletion induced by i.p. injection of an anti-CD3ε antibody (145-2C11). This kind of deletion is probably mediated mainly by cytokines (tumor necrosis factor) generated in the periphery as a result of the massive activation of peripheral T cells, as has been recently shown in a transgenic system with injection of the antigen (35) . As in the experiments described above, the presence of high levels of dMKK-4 did not significantly protect the transgenic thymo-cytes from deletion, and in both transgenic and control animals Ͼ99% of double-positive thymocytes are deleted in 24 h (Fig 3B) .
Therefore, although Fas engagement induces SAPK thymocytes, SAPK activation does not mediate its apoptotic effects. This result agrees with observations made in 293 cells, in which Fas mediates apoptosis mainly through the adaptor protein FADD, and not TRAF2, a protein which mediates SAPK activation (25) . While Fas-induced SAPK activation mediated by a new protein, Daxx, may also play a role in apoptosis in some cell types (36), we find no evidence for this effect in thymocytes.
In conclusion, expression of high levels of a dominantnegative MKK-4 transgene in the thymus shows that Fasinduced apoptosis in this system is not mediated by SAPK activation, since the transgene blocks Fas-induced SAPK activation, but not thymocyte deletion. Our results contrast slightly with those obtained by Nishina et al., who observed a modest protection of thymocytes derived from MKK-4 -/-ES cells from Fas-induced apoptosis (26) . While this might result from a more effective block of MKK-4 activation achieved via gene disruption, analogous experiments recently performed by Swat et al. failed to observe systematic defects in apoptosis in MKK-4 -/-thymocytes (W. Swat et al., pers. commun.). Hence we suspect that the effect observed by Nishina et al. may have resulted from heterogeneity in the characteristics of chimera-derived T lineage cells (37) Our results suggest too that MKK4 is not involved in SAPK activation induced with PMA and ionomycin or through the TCR and CD28. In this light, the lack of effect on T cell development and proliferation that we and others (26) report is not so unexpected. To define the role of this pathway in T cell development and proliferation it will be necessary to identify the SAPKK that mediates activation of SAPK after stimulation with anti-CD3 and anti-CD28 antibodies or PMA and ionomycin, and current experiments in our laboratory are oriented in this direction.
